Studies

45 studies · Download as JSON

• The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agentsMeta-analysis · 2026 · Not yet reviewed
• GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• Effects of glucagon-like peptide-1 analogs on prolactin levels: A secondary analysis of a randomized, double-blind, placebo-controlled crossover trialCrossover trial · 2026 · Not yet reviewed
• GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathwaysAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• Oral Health-Related Adverse Events of GLP-1 Receptor AgonistsPharmacovigilance · 2026 · Study tier 4 · Population unclear · Harm direction
• GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysisRetrospective cohort · 2026 · Facts auto-extracted
• Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic reviewSystematic review · 2026 · Not rated · Different population · Mixed
• Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS dataPharmacovigilance · 2026 · Study tier 4 · Population unclear · Unclear
• Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of conceptAnimal study · 2026 · Facts auto-extracted
• Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issuesPharmacovigilance · 2026 · Facts auto-extracted
• Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity RiskAnimal study · 2026 · Facts auto-extracted
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Facts auto-extracted
• Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian RandomizationMendelian randomization · 2026 · Facts auto-extracted
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Facts auto-extracted
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Facts auto-extracted
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Facts auto-extracted
• Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical TrialsMeta-analysis · 2026 · Facts auto-extracted
• Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS databasePharmacovigilance · 2026 · Facts auto-extracted
• Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase)Pharmacovigilance · 2026 · Facts auto-extracted
• Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Facts auto-extracted
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2026-06-16Regulatory document · 2026 · Not peer reviewed · Facts auto-extracted
• Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 2 · Different population · Benefit
• Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic BenefitsMeta-analysis · 2026 · Facts auto-extracted
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Facts auto-extracted
• Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacyMeta-analysis · 2026 · Facts auto-extracted
• Glycemic Outcomes Associated With GLP-1 Receptor Agonist Shortages in Type 2 DiabetesRetrospective cohort · 2026 · Facts auto-extracted
• Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reportsPharmacovigilance · 2026 · Facts auto-extracted
• Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse modelAnimal study · 2026 · Facts auto-extracted
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Mixed · Industry funded
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
• Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesRandomized trial · 2025 · Facts auto-extracted
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsMeta-analysis · 2025 · Study tier 1 · Different population · Benefit
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear
• Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysisMeta-analysis · 2024 · Facts auto-extracted
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-12Regulatory document · 2023 · Not peer reviewed · Facts auto-extracted
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-09Regulatory document · 2023 · Not peer reviewed · Facts auto-extracted
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-08-05Regulatory document · 2023 · Not peer reviewed · Facts auto-extracted
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-05-03Regulatory document · 2023 · Not peer reviewed · Facts auto-extracted
• Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc AnalysisRandomized trial · 2023 · Facts auto-extracted
• Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitusCell / in-vitro · 2022 · Facts auto-extracted
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialRandomized trial · 2019 · Study tier 1 · Different population · Benefit · Industry funded
• The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes MellitusRandomized trial · 2019 · Facts auto-extracted
• A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-UpRandomized trial · 2019 · Facts auto-extracted
• Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysisMeta-analysis · 2016 · Facts auto-extracted